Effects of dehydroepiandrosterone supplementation on women with poor ovarian response: A preliminary report and review

Objective: To investigate the effect of dehydroepiandrosterone (DHEA) supplementation on women with poor ovarian response (POR). Materials and methods: Women with POR treated with flexible daily gonadotropin-releasing hormone antagonist in vitro fertilization (IVF) cycles at The Reproductive Center...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kuan-Hao Tsui (Autor), Li-Te Lin (Autor), Renin Chang (Autor), Ben-Shian Huang (Autor), Jiin-Tsuey Cheng (Autor), Peng-Hui Wang (Autor)
Format: Knjiga
Izdano: Elsevier, 2015-04-01T00:00:00Z.
Teme:
Online pristup:Connect to this object online.
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_7ccf51ecb4bb49f9b0e9c23ddc828b85
042 |a dc 
100 1 0 |a Kuan-Hao Tsui  |e author 
700 1 0 |a Li-Te Lin  |e author 
700 1 0 |a Renin Chang  |e author 
700 1 0 |a Ben-Shian Huang  |e author 
700 1 0 |a Jiin-Tsuey Cheng  |e author 
700 1 0 |a Peng-Hui Wang  |e author 
245 0 0 |a Effects of dehydroepiandrosterone supplementation on women with poor ovarian response: A preliminary report and review 
260 |b Elsevier,   |c 2015-04-01T00:00:00Z. 
500 |a 1028-4559 
500 |a 10.1016/j.tjog.2014.07.007 
520 |a Objective: To investigate the effect of dehydroepiandrosterone (DHEA) supplementation on women with poor ovarian response (POR). Materials and methods: Women with POR treated with flexible daily gonadotropin-releasing hormone antagonist in vitro fertilization (IVF) cycles at The Reproductive Center in Kaohsiung Veterans General Hospital between January 2013 and October 2013, were enrolled for this prospective study. When patients failed to become pregnant during the first IVF cycle, they were treated with DHEA supplementation (30 mg, 3 times a day, orally) for 3 months (mean 12.2 weeks) before the next IVF cycle. Parameters of biochemical, ultrasound and treatment outcomes were compared before and after DHEA supplementation. Results: Ten patients with a mean age of 36.6 ± 4.2 years were identified. After DHEA treatment, there was a significant increase in antral follicle count, from 2.8 ± 1.0 to 4.1 ± 1.2 (p < 0.05), and anti-Müllerian hormone, from 0.4 ± 0.2 ng/mL to 0.84 ± 0.2 ng/mL (p < 0.001). A significant decrease of Day 3 follicle-stimulating hormone and estradiol, from 14.4 ± 1.7 mIU/mL to 10.1 ± 0.7 mIU/mL and from 51.2 ± 6.3 pg/mL to 35.2 ± 4.2 pg/mL, respectively (both p < 0.001), was noted. Increased numbers of retrieved oocytes (from 2.4 ± 1.1 to 4.2 ± 1.2; p < 0.01), fertilized oocytes (from 1.7 ± 0.5 to 3.8 ± 1.1; p < 0.001), Day 3 embryos (from 1.7 ± 0.5 to 3.7 ± 1.1; p < 0.001) and transferred embryos (from 1.7 ± 0.8 to 2.8 ± 0.8; p < 0.01) were also seen in these women with POR after DHEA treatment. Three women became pregnant after DHEA treatment. Conclusion: The potential benefits of DHEA supplementation in women with POR were suggested by the biochemical parameters and IVF outcomes. 
546 |a EN 
690 |a dehydroepiandrosterone 
690 |a diminished ovarian reserve 
690 |a in vitro fertilization 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n Taiwanese Journal of Obstetrics & Gynecology, Vol 54, Iss 2, Pp 131-136 (2015) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S102845591500025X 
787 0 |n https://doaj.org/toc/1028-4559 
856 4 1 |u https://doaj.org/article/7ccf51ecb4bb49f9b0e9c23ddc828b85  |z Connect to this object online.